Table 2 Published results of clinical trials on the use of CD47 antagonists in lymphomas
From: The landscape overview of CD47-based immunotherapy for hematological malignancies
Drug Name | NCT Number | Sponsor | Protocol | Indication Detail | Enroll-ment | Age/Race/Healthy Volunteers | Phase | Status | Start Date | Design | Endpoint Types | Efficacy Results | Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALX148 | NCT03013218 | ALX Oncology | ALX148 | advanced malignancy and non-Hodgkin lymphoma | 25 (ALX148 monotherapy per week); 11 (ALX148 monotherapy at the highest dose of 30 mg/kg once every other week) | Adults (18 and over) | Phase I | No longer recruiting | 2017–01-06 | Interventional; Treatment; Non-Randomized; Open Label; Single Group Assignment | Safety; Efficacy; Pharmacokinetics; Pharmacodynamics | SD: 27% (ALX148 monotherapy per week), 18% (ALX148 monotherapy at the highest dose of 30 mg/kg once every other week) | [40] |
ALX148 | NCT03013218 | ALX Oncology | ALX148; rituximab | Patients with relapsed or refractory CD20-positive B-cell NHL | 33 | Adults (18 and over) | Phase I | No longer recruiting | 2017–01-06 | Interventional; Treatment; Non-Randomized; Open Label; Single Group Assignment | Safety; Efficacy; Pharmacokinetics; Pharmacodynamics | ORR: 45% | [40] |
TJ011133 | NCT03934814 | I-Mab Bio-Tech (Tianjin) Co., Ltd | lemzoparlimab; rituximab | R/R patients with CD20 positive Non-Hodgkin’s Lymphoma | 8 | Adults (18 and over) | Phase I | Recruiting | 2019–04-16 | Interventional; Treatment; Non-Randomized; Open Label; Single Group Assignment | Safety; Efficacy; Pharmacokinetics; Pharmacodynamics | ORR: 57% | [41] |
IBI-188 | NCT03763149 | Innovent Biologics Inc | letaplimab | advanced/refractory solid tumors or lymphoma | 20 | Adults (18 and over) | Phase I | Completed | 2019–02-19 | Interventional; Treatment; Open Label; Single Group Assignment | Safety; Efficacy; Pharmacokinetics; Pharmacodynamics | / | [42] |
Hu5F9-G4 | NCT02953509 | Forty Seven Inc; Gilead Sciences Inc | Hu5F9-G4; rituximab | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | 22 | Adults (18 and over) | Phase I/II | No longer recruiting | 2016–11-21 | Interventional; Treatment; Non-Randomized; Open Label; Single Group Assignment | Safety; Efficacy; Pharmacokinetics; Pharmacodynamics | ORR: 50% | [43] |
TTI-621 | NCT02663518 | Trillium Therapeutics Inc | TTI-621 | T-Cell Lymphoma | 64 | Adults (18 and over) | Phase I | No longer recruiting | 2016–01-01 | Interventional; Treatment; Non-Randomized; Open Label; Parallel Assignment | Safety; Efficacy; Pharmacokinetics; Pharmacodynamics | ORR (CTCL): 19%; ORR (PTCL): 18% | [44] |
TTI-621 | NCT02663518 | Trillium Therapeutics Inc | 1. TTI-621; rituximab 2. TTI-621 | DLBCL | 35 | Adults (18 and over) | Phase I | No longer recruiting | 2016–01-01 | Interventional; Treatment; Non-Randomized; Open Label; Parallel Assignment | Safety; Efficacy; Pharmacokinetics; Pharmacodynamics | ORR: 21% vs 29% (TTI-621 plus rituximab vs TTI-621 monotherapy) | [44] |
TTI-621 | NCT02890368 | Trillium Therapeutics Inc | TTI-621 | Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome | 35 | Adults (18 and over) | Phase I | Terminated | 2016–09-01 | Interventional; Treatment; Non-Randomized; Open Label; Parallel Assignment | Safety; Efficacy; Pharmacokinetics; Pharmacodynamics |  ≥ 50% reduction in CAILS score: 34% | [45] |
TTI-622 | NCT03530683 | Trillium Therapeutics Inc | TTI-622 | patients with advanced relapsed or refractory lymphoma | 42 | Adults (18 and over) | Phase I | Recruiting | 2018–05-01 | Interventional; Treatment; Non-Randomized; Open Label | Safety; Efficacy; Pharmacokinetics; Pharmacodynamics | ORR: 33% |